Effects of taxotere on murine and human tumor cell lines

Riou, Jean‐François; Naudin, Annette; Lavelle, François

doi:10.1016/s0006-291x(05)81474-3

Cited by 119 publications

(33 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(N.B., this statement applies only to tumour lines that are not resistant to paclitaxel; we, and others (Horwitz et al, 1986) Non-proliferating cells were markedly more resistant to paclitaxel than were cells growing exponentially. Similar findings have recently been reported in N417 small cell lung cancer cells (Riou et al, 1992). It has been recognised for some time that cell cycle specific chemotherapeutic agents are less toxic to non-proliferating cells (Drewinko et al, 1981) and paclitaxel fits this pattern very well.…”

Section: Discussionsupporting

confidence: 85%

Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

Liebmann

Cook²,

Lipschultz³

et al. 1993

Br J Cancer

367

187

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 85%

Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

Liebmann

Cook²,

Lipschultz³

et al. 1993

Br J Cancer

367

187

View full text Add to dashboard Cite

“…Patients receiving the 6-week schedule averaged 3 cycles per patient (range [1][2][3][4][5][6][7][8]. Those that received the 3-week schedule averaged 4 cycles per patient (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Since the number of doses per cycle was less in the 3-week schedule compared to the 6-week schedule, the average number of 12 doses per patient was the same in both groups.…”

Section: Resultsmentioning

confidence: 99%

“…Cells are arrested at the G 2 /M transition resulting in failed cell division and cytotoxicity. 9 Docetaxel is a more potent antimicrotubule agent than paclitaxel in vitro, 10 and has also been shown to be active in a broad range of tumors including carcinomas of the lung, breast, bladder, pancreas, head and neck and ovary. 11,12 Responses to docetaxel have also been observed in patients previously treated with paclitaxel.…”

Section: Introductionmentioning

confidence: 99%

Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer

Bleickardt¹,

Argiris²,

Rich³

et al. 2002

Cancer Biology & Therapy

View full text Add to dashboard Cite

Background. Docetaxel and irinotecan have additive or synergistic activity in vitro and in vivo as well as differing toxicities and unique mechanisms of action. We conducted a phase I trial to determine the maximum-tolerated dose of docetaxel and irinotecan given on a weekly schedule.Methods. Eligible patients had advanced, incurable, solid tumors. Docetaxel was administered as a 1-hour infusion and escalated over four dose levels (25,30, 35, and 40 mg/m 2 ) followed by irinotecan administered over 30 minutes at a fixed dose of 50 mg/m 2 . Treatment was administered weekly for four weeks followed by two weeks of rest. To improve tolerability, the schedule was modified to weekly administration for two weeks with one week of rest, and irinotecan was escalated over 3 dose levels (55, 60, and 65 mg/m 2 ) with docetaxel fixed at 35 mg/m 2 .Results. Forty-four patients were treated and the most common dose-limiting toxicity was diarrhea observed in 11% of patients. Severe neutropenia was rare (grade 4: 2%, grade 3: 23%). Other nonhematologic toxicities included nausea/vomiting, dehydration and fatigue. Partial responses occurred in two patients with pancreatic cancer, and one patient each with non-small cell lung and esophageal cancer.Conclusions. Weekly docetaxel and irinotecan is a promising non-cisplatin doublet with preliminary evidence of activity in advanced solid tumors. Diarrhea is the predominant dose-limiting toxicity but unlike the every 3 weeks schedule myelosuppression is modest. The recommended phase II doses are docetaxel 35 mg/m 2 and irinotecan 60 mg/m 2 on days 1 and 8 of a 21-day schedule. Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers.

show abstract

“…It has been demonstrated in several studies that on a molar basis docetaxel is more potent than paclitaxel as a single drug (Kelland et al, 1992;Riou et al, 1992;Hill et al, 1994;Engblom et al, 1997). In the present stud y, a greater supra-additive e ffect was achieved with the combination of docetaxel and cisplatin compared with the Table 4 The dose dependence of additive and supra-additive cytotoxic effect.…”

Section: Discussionmentioning

confidence: 99%

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

et al. 1998

View full text Add to dashboard Cite

SummaryThe purpose of this study was to compare the growth-inhibitory effect of cisplatin-paclitaxel with that obtained with a cisplatin-docetaxel combination and to assess the type of interaction. Concomitant use of taxanes and cisplatin was studied in seven human ovarian carcinoma cell lines, using the 96-well plate clonogenic assay. Chemosensitivity was expressed in terms of IC 50 values, the drug concentration causing 50% inhibition of clonogenic survival. The type of interaction was studied using the area under the survival curve ratios (AUC ratios) obtained by numerical integration. Comparison of the AUC ratio and the surviving fraction (SF) value after taxane alone was made using Student's t-test. The influence of the drug concentration was tested by one-way analysis of variance (Anova). A supra-additive or additive effect was seen when seven ovarian carcinoma cell lines were exposed to paclitaxel or docetaxel concomitantly with cisplatin. A supra-additive effect was found in four cell lines (UT-OC-3, UT-OC-4, UT-OC-5 and SK-OV-3) after simultaneous use of cisplatin with all docetaxel concentrations tested, and in two cell lines (UT-OC-4 and SK-OV-3) when cisplatin was used concomitantly with paclitaxel. A more pronounced supra-additive effect was seen with the combination of cisplatin and docetaxel. The degree of supra-additivity was dose dependent, with increasing synergy after a higher taxane dose. The data obtained in this study suggest that a supra-additive or additive effect can be achieved in ovarian carcinoma with the concomitant use of cisplatin and a taxane. for cervical cancer 30 and 5 years before the diagnosis of ovarian carcinoma. The donors of the UT-OC-1 and UT-OC-3 cell lines had not received any cytotoxic therapy before the establishment of the cell lines. Keywords Cell cultureBefore the experiments, the cells were kept in logarithmic growth in T25 culture flasks by passing weekly in Dulbecco's modified Eagle's minimal essential medium (DMEM) containing 2 mM L-glutamine, 1% non-essential amino acids, 100 U ml -1 streptomycin, 100 U ml -1 penicillin and 10% fetal bovine serum (FBS). Cells in mid-logarithmic growth (40-60% confluence) were used for the experiments and fed with fresh medium on the day before plating. Drug preparationCisplatin (Platinol) 0.5 mg ml -1 was diluted with growth medium to get a stock solution of 100 µg ml -1 . Final cisplatin dilutions of 0.05-0.6 µg ml -1 were used, and new stock solutions were made for each experiment. Paclitaxel (Taxol, kindly provided by BristolMyers Squibb) was initially dissolved in 0.9% sodium chloride to get a solution of 0.1 mM. Stock solutions were prepared in Ham's F-12 medium containing 10% FBS to obtain a solution of 100 nM, and stored at -40°C. Final dilutions of 0.4-5 nM paclitaxel were used for the experiments. Docetaxel (Taxotere, 807.9 mg, kindly provided by Rhone-Poulenc Rorer) was diluted in 1 ml of ethanol to obtain a stock solution of 0.1 mM and stored at -40°C. These solutions were further diluted in sterile water to obtain...

show abstract

Effects of taxotere on murine and human tumor cell lines

Cited by 119 publications

References 11 publications

Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

Contact Info

Product

Resources

About